MichBio Announces New Slate of Board Officers for 2007-08
MichBio, Michigan's life sciences industry association, announced June 11 its board of directors has elected a new slate of officers for 2007-08:
• Edwrd Pagani has been named chairman of MichBio. Pagani is senior director of strategic alliances for Pfizer Global Research and Development. Pagani joined Pfizer in 1995 after holding positions at Sterling Drug and Sterling Winthrop.
Pagani succeeds Randal Charlton, who retired from the board after serving three years as its chairman. Charlton is interim director of Detroit's TechTown research and technology park, and recently retired as chairman and CEO of Asterand, a Detroit human tissue bank that provides research material to drug discovery companies.
• Michael Kurek is president of MichBio. Kurek has been a partner with Biotechnology Business Consultants in Ann Arbor since 2002, after serving in executive positions with numerous biotech firms for 30 years.
• Paul Morris, MichBio’s assistant treasurer and a senior manager with Grant Thornton, was named the association's treasurer and will chair its finance committee. Ryan Noel, manager of finance with Pfizer Global Research and Development, succeeds Morris as assistant treasurer.
• Christina DeHayes, general counsel with Asterand, was named new board secretary, succeeding Asterand’s senior director of finance and administration, John Stchur.
IR BioSciences Appoints Lance Gordon to Its Board of Directors
Lance Gordon, who served as president and CEO of VaxGen from 2001 to earlier this year, has been named to the board of directors of IR BioSciences Holdings of Scottsdale, Ariz. IR BioSciences is focused on the research and development of countermeasures for multiple homeland security bioterrorism threats.
Gordon is a member of the US National Vaccines Advisory Committee, the Sabin Vaccine Institute Board of Trustees, the Expert Panel of the Meningitis Vaccine Project, the American Association of Immunologists and the American Society for Microbiology. He received a BA in Zoology from the University of California at Humboldt and a PhD in Biomedical Science, Immunology and Molecular Genetics from the University of Connecticut at Farmington.
Avid Radiopharmaceuticals Names New Board Member
Avid Radiopharmaceuticalshas named Ernest Mario, chairman of Reliant Pharmaceuticals, to its board of directors. Based in Philadelphia, Avid develops molecular-imaging agents for early detection of neurological disorders.
Mario — Reliant’s chief executive officer from 2003 to 2006 — serves on the boards of directors of Boston Scientific, Maxygen, Alexza Pharmaceuticals, and Pharmaceutical Product Development.
A past chairman of the American Foundation for Pharmaceutical Education, Mario also serves as an advisor to the pharmacy schools at the University of Maryland, the University of Rhode Island and The Ernest Mario School of Pharmacy at Rutgers University. He holds a BS in pharmacy from Rutgers, and an MS and a PhD in physical sciences from the University of Rhode Island. Earlier this year he received the Remington Medal, the highest honor the American Pharmacists Association bestows on a US pharmacist.
Two New Brokers Join Richards Barry Joyce & Partners
Richards Barry Joyce & Partners has added two experienced brokers to the commercial real estate advisory firm:
• Jay Nugent has joined RBJ’s suburban leasing group as a vice president. He came to the firm from Jones Lang LaSalle, where he was an assistant vice president. Nugent — who has helped lease and sell more than 4 million square feet of space over the past six years — earned a BS from Arizona State University and volunteers with Big Brothers of Massachusetts.
• Eric Smith has joined RBJ’s Cambridge leasing group as an assistant vice president. He previously worked for CB Richard Ellis/New England, where he assisted clients that included lab space developer Alexandria Real Estate Equities, the Massachusetts Institute of Technology, Alinea Pharmaceuticals, Biomodels, and Gene Network Sciences. He graduated from the University of Vermont.
Aldagen Adds Martin Murphy Jr. to Board of Directors
Aldagen, a Durham, NC,developer of clinical-stage regenerative therapies, has appointed Martin Murphy Jr. to its board of directors. Murphy is the founding chairman and CEO of AlphaMed Consulting, which provides strategic support for academic cancer centers and cancer drug development programs for global pharmaceutical and biotechnology companies. He is founding executive editor of the international peer-reviewed journals Stem Cells and The Oncologist.
Murphy is a member of the scientific advisory boards of Pappas Ventures and Almac Diagnostics, as well as a board member of the American Cancer Society Foundation, the Foundation for the National Institutes of Health, Jennerex Pharmaceuticals, and C-Change (formerly the National Dialogue on Cancer). At the request of former president George H.W. Bush, Murphy has been convener of the non-profit CEO Roundtable on Cancer since its origin in 2001.